May 8 |
Cartesian Therapeutics GAAP EPS of -$10.50, revenue of $5.84M
|
May 8 |
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
Apr 22 |
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
|
Apr 10 |
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
|
Apr 4 |
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
Mar 28 |
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
|
Mar 21 |
Cartesian Therapeutics Director Acquires 3.2% More Stock
|
Mar 19 |
LivePerson And 2 Other Stocks Under $2 Insiders Are Buying
|
Mar 7 |
Cartesian Therapeutics GAAP EPS of -$1.66 misses by $1.64, revenue of $26M beats by $15.4M
|
Mar 7 |
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
|